James Knobelsdorf - Knoblesville IN, US Sheryl Hays - Ann Arbor MI, US Charles J. Stankovic - Saline MI, US Kimberly S. Para - Ann Arbor MI, US Michael K. Connolly - Ypsilanti MI, US Paul Galatsis - Ann Arbor MI, US William Harter - Chelsea MI, US Aurash B. Shahripour - Ann Arbor MI, US Mark Stephen Plummer - Dexter MI, US Beth Lunney - San Diego CA, US Bernd Janssen - Marlborough MA, US Jay Bradford Fell - Longmont CO, US
The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.
Hydroxamate Inhibitors Of Interleukin-1.Beta. Converting Enzyme
Hamish John Allen - Shrewsbury MA Kenneth Dale Brady - Worcester MA Bradley William Caprathe - Livonia MI Paul Galatsis - Ann Arbor MI John Lodge Gilmore - Ann Arbor MI Sheryl Jeanne Hays - Ann Arbor MI Robert Vincent Talanian - Harvard MA Nigel Walker - Dossenheim, DE Joseph Scott Warmus - Ann Arbor MI
Assignee:
Warner-Lambert Company - Morris Plains NJ BASF Aktiengesellsschaft - Ludwigshafen
The present invention relates to compounds that are inhibitors of interleukin-1. beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1. beta. converting enzyme.
Novel Imidazo[4,5-C]Quinoline Derivatives As Lrrk2 Inhibitors
- New York NY, US Thomas Allen CHAPPIE - Carlisle MA, US Jinshan Michael CHEN - Madison CT, US Jotham Wadsworth COE - Niantic CT, US Karen Jean COFFMAN - Pawcatuck CT, US Paul GALATSIS - Newton MA, US Michelle Renee GARNSEY - Providence RI, US Christopher John HELAL - Mystic CT, US Jaclyn Louise Henderson - Cambridge MA, US Bethany Lyn KORMOS - Somerville MA, US Ravi G. KURUMBAIL - East Lyme CT, US Luis Angel MARTINEZ-ALSINA - Gales Ferry CT, US Martin Youngjin PETTERSSON - Littleton MA, US Matthew Richard REESE - Mystic CT, US Colin Richard ROSE - Quaker Hill CT, US Antonia Friederike STEPAN - Biberach an der Riss, DE Patrick Robert VERHOEST - Newton MA, US Travis T. WAGER - Brookline MA, US Joseph Scott WARMUS - Ledyard CT, US Yuan ZHANG - East Lyme CT, US
International Classification:
C07D 471/04
Abstract:
The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
- New York NY, US Paul Galatsis - Newton MA, US Michelle Renee Garnsey - Providence RI, US Christopher John Helal - Mystic CT, US Jaclyn Louise Henderson - Cambridge MA, US Bethany Lyn Kormos - Somerville MA, US Ravi G. Kurumbail - East Lyme CT, US Luis Angel Martinez-Alsina - Gales Ferry CT, US Martin Youngjin Pettersson - Littleton MA, US Antonia Friederike Stepan - Biberach An Der Riss, DE Travis T. Wager - Brookline MA, US
International Classification:
C07D 471/04 C07D 471/14
Abstract:
The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Youtube
Why the majority is always wrong | Paul Rulke...
This talk was given at a local TEDx event, produced independently of t...
Duration:
11m 26s
Physics and Consciousness with Saul-Paul Sirag
Saul-Paul Sirag is author of ADEX Theory: How the ADE Coxeter Graphs U...
Duration:
1h 5m 54s
DJ PAUL G Hosting DJ Kimono - Melodic and Ind...
colab between the two DJ's prior to there first Firefly event together...
Duration:
1h 10m 54s
Precognitive Dreams with Paul Kalas
Paul Kalas is adjunct professor of astronomy at the University of Cali...
Duration:
52m 15s
Paul Slovic | Confronting the Deadly Arithmet...
Paul Slovic discusses human perception towards mass tragedies and loss...
Duration:
50m 22s
Lower back and glutes workout - Kit & Krysta:...
Hi everyone, here is a little lower back workout video that will also ...
Duration:
13m 46s
Ab workout session - Kit & Krysta: Karate & C...
Hi everyone, here is a 160 rep abdominal workout. Feel free to adjust ...
Duration:
11m 40s
Squash: Paul Coll v Ali Farag - Greatest Batt...
With Paul Coll going to World No.1 in the March rankings, we take a lo...